BioNTech SE - American Depositary Shares (BNTX)
104.51
+2.30 (2.25%)
NASDAQ · Last Trade: Oct 2nd, 10:07 PM EDT
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's resilience. Despite prevailing anxieties, including a looming U.S. government shutdown and a disappointing jobs report, healthcare equities
Via MarketMinute · October 2, 2025
A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human cells. This innovation, spearheaded by bioengineers at the University of California San Diego, promises to fundamentally transform our understanding of complex diseases
Via MarketMinute · October 2, 2025
Pfizer, BioNTech’s Updated COVID-19 Vaccine Shows Robust Immune Response In Late-Stage Study – More Details Insidestocktwits.com
Via Stocktwits · September 8, 2025
Why Did BioNTech Stock Surge 10% Pre-Market Today?stocktwits.com
Via Stocktwits · September 5, 2025
The company's push deeper into a hot new technology, plus good news from a top collaborator, put the shine on its equity.
Via The Motley Fool · October 1, 2025
Investors were cheered by two pieces of good news concerning the biotech's most famous product.
Via The Motley Fool · September 22, 2025
Moderna stock toppled Friday after advisors to the CDC and Prevention ended the universal recommendation for Covid vaccines.
Via Investor's Business Daily · September 19, 2025
The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters.
Via Investor's Business Daily · September 18, 2025
Moderna's updated Spikevax shows strong antibody response and safety, targeting dominant COVID-19 variants like LP.8.1 in high-risk and older adults.
Via Benzinga · September 16, 2025
Markets closed Friday in mixed fashion as economic uncertainty and politics clashed with earnings optimism. Oracle's rollercoaster continues, RFK Jr. rattles vaccine makers, and the Fed appears poised to begin its rate-cut cycle next week. All this while tech, AI, and takeover buzz kept parts of the market energized.
Via Chartmill · September 15, 2025
Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biotech trial updates and mixed analyst calls pressured others.
Via Benzinga · September 14, 2025
The type of vaccine it's most famous for might be cast in a very unflattering light in the very near future..
Via The Motley Fool · September 12, 2025
Shares of COVID-19 vaccine makers are trading lower Friday. Vaccine stocks fell Friday on a Washington Post report that Trump administration officials plan to link the shots to 25 child deaths.
Via Benzinga · September 12, 2025
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.
Via Investor's Business Daily · September 10, 2025
Pfizer and BioNTech's LP.8.1 COVID-19 vaccine boosts antibodies 4-fold in high-risk adults, with no new safety concerns reported.
Via Benzinga · September 8, 2025
BioNTech and Bristol Myers report strong interim results for pumitamig plus chemo in lung cancer, showing high response rates.
Via Benzinga · September 8, 2025
Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer.
Via Investor's Business Daily · September 8, 2025
The company might be close to commercializing its most advanced pipeline program.
Via The Motley Fool · September 5, 2025
Via Benzinga · September 5, 2025
It's unprecedented times for the Covid vaccine market, experts say. And Pfizer and Moderna remain under significant pressure.
Via Investor's Business Daily · September 5, 2025
The company's DualityBio-partnered drug met the pre-specified bar for success in a pivotal study.
Via Investor's Business Daily · September 5, 2025
BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China.
Via Benzinga · September 5, 2025
Daskalakis resigned due to political interference in CDC, fears harm will come from new direction. CDC leaders also resign in protest.
Via Benzinga · September 1, 2025
Marvell, Hormel, and Keurig Dr Pepper led weekly large-cap losers on weak guidance and analyst downgrades.
Via Benzinga · August 31, 2025